الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
This study aimed at assessing the possible antitumor efficacy and safety of high dose of LPZ pretreatment in patients with stage II and stage III breast cancer receiving neo-adjuvant chemotherapy. In this single blinded, randomized placebo-controlled study, 66 women with stage II and III breast cancer were randomly distributed into two groups; the LPZ group (n=33) which started LPZ capsules 60 mg orally bid 4 days before starting NAC and till the end of chemotherapy cycles and the control group (n=33) which received placebo capsules and the same NAC regimen. Evaluation of tumor response using RECIST criteria and assessment of P-gp and Ki-67 levels were done for the two groups before and after treatment. Adverse events were documented and graded using (NCI-CTCAE, v5, 2017). The results obtained with the current study revealed that, LPZ produced a more favorable response especially within luminal B/HER2 negative subtype breast cancer. Lansoprazole group showed non-significant but clinically important decline in P-gp and Ki-67 levels as compared to the control group. Dyspepsia was the only significant adverse effect reported with LPZ. We concluded that, however LPZ didn’t produce a statistically significant anti-tumor effect as compared to placebo; it exerted a clinically important improvement through increasing the number of patients who achieved complete response. Lansoprazole Co-administration with Neoadjuvant Chemotherapy in Women with Breast Cancer Additionally, the high dose of LPZ used during this study seems tolerable and safe. We recommend further large scale, more longitudinal, multi-centers studies in order to re-evaluate the anti-tumor activity of proton pump inhibitors especially lansoprazole.